We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
South Korean (KOSPI) Pharma Industry Analysis
UpdatedJul 01, 2022
DataAggregated Company Financials
Companies96
- 7D1.7%
- 3M-16.0%
- 1Y-39.7%
- YTD-23.3%
The Pharma industry is up 5.8% in the last week, with SK Biopharmaceuticals up 6.8%. However, the industry is down 39% over the past year. Earnings are forecast to grow by 41% annually.
Industry Valuation and Performance
Has the South Korean Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Sat, 02 Jul 2022 | ₩47.6t | ₩26.7t | ₩475.9b | 20.7x |
| Mon, 30 May 2022 | ₩53.5t | ₩26.6t | ₩555.9b | 23.8x |
| Wed, 27 Apr 2022 | ₩56.1t | ₩26.1t | ₩674.3b | 28.3x |
| Fri, 25 Mar 2022 | ₩56.5t | ₩25.7t | ₩705.9b | 24.4x |
| Sun, 20 Feb 2022 | ₩52.7t | ₩25.0t | ₩934.5b | 23x |
| Tue, 18 Jan 2022 | ₩55.4t | ₩25.0t | ₩934.5b | 23.1x |
| Thu, 16 Dec 2021 | ₩62.0t | ₩25.0t | ₩934.5b | 26x |
| Sat, 13 Nov 2021 | ₩59.7t | ₩24.7t | ₩875.4b | 23.6x |
| Mon, 11 Oct 2021 | ₩62.4t | ₩24.7t | ₩876.1b | 23.7x |
| Wed, 08 Sep 2021 | ₩72.1t | ₩26.0t | ₩960.6b | 38.7x |
| Fri, 06 Aug 2021 | ₩72.1t | ₩25.3t | ₩928.3b | 41.5x |
| Mon, 10 May 2021 | ₩69.3t | ₩24.9t | ₩915.5b | 34.8x |
| Sun, 31 Jan 2021 | ₩76.0t | ₩24.6t | ₩897.5b | 35.5x |
| Wed, 04 Nov 2020 | ₩68.8t | ₩24.4t | ₩499.4b | 27.5x |
| Sat, 08 Aug 2020 | ₩69.8t | ₩24.0t | ₩524.2b | 27.7x |
| Fri, 01 May 2020 | ₩40.3t | ₩23.6t | ₩732.3b | 21.1x |
| Mon, 03 Feb 2020 | ₩37.2t | ₩23.1t | ₩621.5b | 26.6x |
| Thu, 07 Nov 2019 | ₩39.4t | ₩21.8t | ₩547.5b | 24.5x |
| Wed, 31 Jul 2019 | ₩37.1t | ₩21.1t | ₩625.0b | 23.4x |
Median PE Ratio
25.9x
Current Industry PE
- Investors are optimistic on the industry, and appear confident in long-term growth rates.
- The industry is trading at a PE ratio of 99x which is higher than its 3-year average PE of 81.2x.
- The industry's 3-year average PS ratio 2.4x is higher than the industry's current PS ratio of 1.8x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 8.7% per year over the last three years.
- Meanwhile revenues for these companies have grown 8.2% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does South Korean Pharma compare with similar industries?
| KR Market | -1.34% | |
| Healthcare | -1.07% | |
| Pharma | 1.73% | |
| Pharma | 1.73% | |
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A069620 Daewoong pharmaceuticalLtd | ₩173.00k | 6.5% +₩116.2b | 0.3% | PE31.2x | |
| A039200 Oscotec | ₩26.90k | 7.4% +₩58.3b | -34.9% | PS209.8x | |
| A003090 Daewoong | ₩26.95k | 5.5% +₩58.2b | -41.7% | PE11.3x | |
| A068760 Celltrion Pharm | ₩78.50k | 1.8% +₩52.6b | -50.3% | PE113.4x | |
| A004310 Hyundai Pharmaceutical | ₩5.73k | 43.8% +₩48.1b | -20.3% | n/a |